Indivior (INDV) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
13 May, 2026Opening remarks and agenda
Meeting called to order and conducted virtually to ensure broad shareholder access.
Board members, executive team, auditors, and inspector of election participated remotely.
Notice of meeting and quorum confirmed in accordance with legal requirements.
Shareholder proposals
Election of directors for the next term was the first item of business.
Advisory vote on executive compensation (say on pay) presented as the second proposal.
Advisory vote on the frequency of future say on pay votes offered as the third proposal.
Ratification of PricewaterhouseCoopers as independent auditor for 2026 was the fourth proposal.
Overview of voting outcomes
All director nominees were elected.
Executive compensation and auditor ratification proposals received sufficient approval.
Annual frequency for future say on pay votes was approved.
Final results to be reported in a Form 8-K filing within four business days.
Latest events from Indivior
- Merger forms a $2.2B CNS biopharma leader with strong growth, profitability, and synergies.INDV
Corporate presentation - Merger creates a CNS leader with $2.2B revenue, $888M EBITDA, and $125M in synergies.INDV
Q2 2026 & Merger - SUBLOCADE's growth accelerates with DTC and commercial gains as diversification plans advance.INDV
Jefferies Global Healthcare Conference 2026 - Q1 2026 delivered record EBITDA, 19% revenue growth, and raised guidance on SUBLOCADE strength.INDV
Q1 2026 - Strong financial results, U.S. redomicile, and robust governance mark a pivotal year.INDV
Proxy filing - Key votes include director elections, executive pay, and auditor ratification for 2026.INDV
Proxy filing - Record SUBLOCADE growth, margin gains, and a $400M share repurchase program set up further acceleration.INDV
Q4 2025 - SUBLOCADE growth, cost cuts, and organizational overhaul drive the 2025–2026 strategy.INDV
Morgan Stanley 23rd Annual Global Healthcare Conference - SUBLOCADE growth drove FY 2024 gains, but 2025 faces a 17% revenue decline from SUBOXONE Film erosion.INDV
Q4 2024